Venetolax with Azacitidine Drains Fuel from AML Stem Cells
- PMID: 30609400
- DOI: 10.1016/j.stem.2018.12.005
Venetolax with Azacitidine Drains Fuel from AML Stem Cells
Abstract
In Nature Medicine, Pollyea et al. (2018) recently reported a remarkable overall response of newly diagnosed elderly acute myeloid leukemia patients to a venetoclax and azacitidine combination in a new clinical trial. This treatment reduced succinate dehydrogenase glutathionylation, impaired the tricarboxylic acid cycle, and depleted ATP in leukemia stem cells.
Copyright © 2018 Elsevier Inc. All rights reserved.
Comment on
-
Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia.Nat Med. 2018 Dec;24(12):1859-1866. doi: 10.1038/s41591-018-0233-1. Epub 2018 Nov 12. Nat Med. 2018. PMID: 30420752 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
